CAR‐T cells with mucin‐1 (MUC1) and prostate stem cell antigen (PSCA) cannot eliminate tumor cells but the combined therapy showed a better anti‐tumor effect than single CAR‐T cell therapy [63]. This evidence concerns the gene PSCA and neoplasm.